Antivenom market seen reaching $2.91 billion by 2030

By AI, Created 11:41 AM UTC, May 20, 2026, /AGP/ – The Business Research Company projects the global antivenom market will grow from $2.04 billion in 2025 to $2.91 billion by 2030, driven by snakebite cases, recombinant therapies and expanded healthcare access. North America led the market in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - Antivenom is a life-saving treatment for venomous bites and stings, and demand is rising as snakebite burden remains high worldwide. - The market forecast points to steady growth in treatments, diagnostics and regional manufacturing as health systems seek faster and more effective response options. - The World Health Organization has set a goal to cut snakebite mortality and disability by 50% by 2030, underscoring the public health stakes.

What happened: - The Business Research Company released its Antivenom Global Market Report 2026, covering market size, trends and forecasts for 2026-2035. - The report estimates the antivenom market will rise from $2.04 billion in 2025 to $2.18 billion in 2026. - The report projects the market will reach $2.91 billion by 2030. - The forecast implies a 6.8% compound annual growth rate in 2026 and 7.5% CAGR through 2030. - The report was published May 8, 2026, in London. - Download a free sample of the report.

The details: - Antivenom, also called antivenin, is an antibody-based therapy used soon after envenomation to neutralize venom toxins. - The treatment is used for bites and stings from venomous creatures including rattlesnakes, moccasins and copperheads. - Historical growth factors include limited antivenom supply, high bite incidence in rural areas, traditional manufacturing methods, regulatory hurdles and low awareness among healthcare professionals. - Future growth drivers include recombinant antivenom technology, government funding for antivenom programs, more exotic pet ownership, stronger healthcare infrastructure in developing regions and precision medicine approaches. - Key market trends include recombinant production, cold chain optimization, rapid diagnostic tools for venom identification, growth in regional manufacturing and personalized antivenom therapies. - The report says North America held the largest market share in 2025. - The Asia-Pacific region is expected to post the fastest growth during the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - View the full report.

Between the lines: - The market outlook ties a basic medical need to broader shifts in biotech and health system capacity. - Recombinant and personalized approaches suggest the category is moving beyond older animal-derived production methods. - WHO’s snakebite estimates point to sustained unmet need, especially in regions with limited access to fast treatment. - North America’s lead likely reflects stronger healthcare infrastructure, while Asia-Pacific’s growth signals rising demand and expanding access.

What’s next: - The market will likely track progress in recombinant antivenoms, diagnostics and regional production capacity. - Health systems in higher-burden regions may push for better cold chain logistics and faster venom identification tools. - WHO’s 2030 snakebite target could influence funding, procurement and public health programs tied to antivenom access.

The bottom line: - Antivenom is moving from a niche emergency treatment into a growing global market shaped by public health need, biotech innovation and access gaps.